This investigational drug reduces neurotoxicity by knocking out the ICP34.5 gene of HSV-1 and enhances antigen presentation by knocking out the ICP47 gene while also inserting the GM-CSF gene to boost anti-tumor immune response [132,133,134]. Here, CSF2 is linked to neoplasm.